Sarepta Therapeutics (SRPT) Current Leases (2022 - 2023)
Sarepta Therapeutics (SRPT) posted quarterly Current Leases of $17.8 million for Q4 2023, up 15.21% year-over-year from $15.5 million in Q4 2022, and up 15.21% quarter-over-quarter from $15.5 million in Q4 2022.
Powered by 
Analysis
Sarepta Therapeutics (SRPT) Current Leases (2022 - 2023) Analysis & Trends
Sarepta Therapeutics' Current Leases history runs 2 years deep, the most recent figure standing at $17.8 million for Q4 2023.
- In Q4 2023, Current Leases rose 15.21% year-over-year to $17.8 million; the TTM figure through Dec 2023 stood at $17.8 million (up 15.21% YoY), while the FY2023 annual figure was $17.8 million, up 15.21% from the prior year.
- Current Leases for Q4 2023 stood at $17.8 million, up from $15.5 million in the prior quarter.
- The five-year high for Current Leases was $17.8 million in Q4 2023, with the low at $15.5 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 11.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 16.75 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 21.95 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Sarepta Therapeutics | 2.36 Bn | 1.57 Bn | 251.87 Mn | - |